Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: IMHO. Nobody knows zilch

There was only ONE license announced for the quarter that we'll receive the report on today. That was Cymer. According to my "count", Cymer represented the 86th company to license, but that is certainly at best a good guess. PTSC won't respond to e-mails requesting clarification, nor will they provide transparency on their own regarding this issue.

Additionally, we know that per their lawyers, it was claimed that at least 91 companies had licensed the MMP as of 12/23/11.

As for PDSG, the latest info is that we have hired an investment banking firm to sell or partner PDSG. I anticipate that will come at a pretty severe discount to our actual investment, but perhaps that's better than death by paper-cut, that it represents currently due to its inability to generate revenue.

I'll be interested to see what the balance sheet shows for the last quarter. Hopefully, there will be an improvement in the total assets of $10.9M that was reflected last quarter. If not, certainly, if the decrease in that line is more than the $1.2M that was reported last time, I'll be concerned about PTSC's prospects short term, as it will reflect, IMO, an URGENCY to PTSC's financial situation, that to date has been less concerning. I say that because we are entering the litigation phase and if we reflect a small warchest with which to battle, IMO, ALL of our options will be weakened, whether it's settlement, litigation, or licensing to supplement that warchest and feed the legal machine.

Share
New Message
Please login to post a reply